FiercePharmaOriginal article
{"a":[{"_":"Apollo inks €3B equity deal for stake in Bayer's contraceptives business","$":{"href":"/pharma/bayer-inks-eu3b-equity-deal-apollo-stake-contraceptives-business","hreflang":"en"}}]}
Long-acting reversible contraceptivesPositive
AI Analysis
Summary
Bayer secured €3 billion ($3.4 billion) in equity funding from Apollo for a minority non-controlling stake in its newly established long-acting reversible contraceptives business.
Outcome Details
Equity investment deal valuing minority stake at €3 billion ($3.4 billion)
Importance:7/10
Sentiment:
0.60
M&Aequity dealcapital infusioncontraceptivesasset manager
Related Companies
Read the original article
Published by FiercePharma on July 10, 2026 11:06 AM